Skip to main navigation
Skip to search
Skip to main content
Search All UT System Experts
University of Texas Southwestern Medical Center Home
Home
Profiles
Research units
Equipment
Research output
Search by expertise, name or affiliation
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
VERTIS-CV Investigators
Internal Medicine
Cardiology
Research output
:
Contribution to journal
›
Article
›
peer-review
162
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol
100%
Safety
29%
Type 2 Diabetes Mellitus
22%
Placebos
20%
Heart Failure
14%
Cardiovascular Diseases
14%
Sodium-Glucose Transporter 2 Inhibitors
14%
Symporters
13%
European Union
11%
Peripheral Arterial Disease
11%
Kidney Diseases
10%
Cerebrovascular Disorders
10%
Renal Dialysis
8%
Coronary Artery Disease
8%
Creatinine
8%
Hospitalization
7%
Myocardial Infarction
7%
Stroke
6%
Transplants
6%
Kidney
5%
Serum
4%
Therapeutics
1%